A decision tool for Liver Transplantation based on molecular signature

Informations projet

HepatoPredict

N° de convention de subvention: 827173

DOI

10.3030/827173

Projet clôturé

Date de signature de la CE 9 Août 2018

Date de début 1 Août 2018

Date de fin 30 Novembre 2018

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

OPHIOMICS - INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SA
Portugal

Periodic Reporting for period 1 - HepatoPredict (A decision tool for Liver Transplantation based on molecular signature)

Période du rapport: 2018-08-01 au 2018-11-30

Résumé du contexte et des objectifs généraux du projet

From August 1st until November 30th, 2018, Ophiomics carried out an extensive feasibility study for their innovative decision tool for Liver Transplantation based on molecular signature. The objective was to address the feasibility of technical activities to ensure HepatoPredict validation on international clinical centres and enforce commercialization and exploitation strategy of the project by means of a FTO Analysis, a detail business plan and a financial feasibility assessment.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

We developed a technical feasibility to analyse the technical requirements to optimize HepatoPredict algorithms, as well as lab procedures. We also performed a detailed list of clinics centres for the validation studies and the procedures to carry them out. We also defined the industrialization plan and updated the Workpackages required to reach the innovation to the market. We currently have a patent pending and we have developed an IPR strategy to obtain a distinctive brand for our product. We carried out a patent search analysis and we concluded that Ophiomics has not infringed on any established IP. Based on these results we decided to expand our protection with a European Unitary Patent.
We developed a business feasibility assessment involved contacting key stakeholders, end-users, and potential partners. In-depth interviews were carried out with all of these parties. This built up a picture of the customer pains, and the market where Ophiomics would enter. At first glance, it is clear that the Liver cancer diagnostic market and the transplantation market are expanding, and the dependent users are critically unsupported by the current solutions.
Finally, we carried out a financial assessment in which we performed an in-depth cost/benefit analysis and we evaluated the total investment requirements to bring HepatoPredict to the market.
For all that reasons, we conclude that the HepatoPredict project is feasible and go therefore ahead with a Phase 2 preparation

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Phase1 Feasibility Study gave to our company the opportunity to expand the scope of our development, having a better understanding of client´s and competitor´s needs. Also, we have acquired a better idea of our technical requirements and our IPR management. Now we have a more strategic approach to our commercial and dissemination activities, as well as a better relationship with KOLs and international business support organisations that will increase the reputation and visibility of our company.

image-1.png